Prime Medicine PRME
NASDAQ PRME
$4.30 +0.40 (+10.26%)
At close: Nov 11, 2026 · 4:00 PM EST

Prime Medicine (PRME) Price to Sales (2024 - 2026)

Updated

Prime Medicine's Price to Sales came in at 163.74 for Q2 2026, up 144.5% from 66.96 a year earlier and up 5.1% from the prior quarter.

Analysis

Prime Medicine (PRME) Price to Sales (2024 - 2026) Analysis & Trends

For FY2025, Prime Medicine's Price to Sales was 111.44, down 13.2% from FY2024.

  • Going back by year, Price to Sales was 128.39 in FY2024.
  • The five-year range for quarterly Price to Sales is 66.96 (Q2 2025) to 1421.57 (Q1 2024).
  • Year-over-year, Price to Sales increased in two of the last six quarters, with an average decline of 0.3%.
  • Business Quant data shows PRME's Price to Sales at 155.81 (Q1 2026), 111.44 (Q4 2025) and 167.13 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Prime Medicine 704.88 Mn 469.45 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 153.32
Mar 31, 2026 135.17
Sep 30, 2025 167.13
Jun 30, 2025 66.96
Mar 31, 2025 67.87
Dec 31, 2024 128.39
Sep 30, 2024 634.49
Jun 30, 2024 1,043.92
Mar 31, 2024 1,421.57
API Access

Prime Medicine Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=PRME&period=max&api_key=YOUR_API_KEY